Cargando…

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis

OBJECTIVE: Inaccessibility of the inflammation compartmentalized to the central nervous system (CNS) may underlie the lack of efficacy of immunomodulatory treatments in progressive multiple sclerosis (MS). The double blind combination of Rituximab by IntraVenous and IntraThecAl injection versus plac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komori, Mika, Lin, Yen Chih, Cortese, Irene, Blake, Andrew, Ohayon, Joan, Cherup, Jamie, Maric, Dragan, Kosa, Peter, Wu, Tianxia, Bielekova, Bibiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774261/ https://www.ncbi.nlm.nih.gov/pubmed/27042677 http://dx.doi.org/10.1002/acn3.293

Ejemplares similares

Pharmacodynamic effects of daclizumab in the intrathecal compartment
por: Komori, Mika, et al.
Publicado: (2017)

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
por: Lin, Yen Chih, et al.
Publicado: (2015)

Cerebrospinal Fluid IL-12p40, CXCL13 and IL-8 as a Combinatorial Biomarker of Active Intrathecal Inflammation
por: Bielekova, Bibiana, et al.
Publicado: (2012)

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment
por: Kosa, Peter, et al.
Publicado: (2016)

Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes
por: Natrajan, Muktha S., et al.
Publicado: (2015)

Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis
por: Milstein, Joshua L., et al.
Publicado: (2019)

Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity
por: Masvekar, Ruturaj, et al.
Publicado: (2021)

Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects
por: Stein, Jason, et al.
Publicado: (2018)

Finger and foot tapping as alternative outcomes of upper and lower extremity function in multiple sclerosis
por: Tanigawa, Makoto, et al.
Publicado: (2017)

Idebenone does not inhibit disability progression in primary progressive MS
por: Kosa, Peter, et al.
Publicado: (2020)

Confounder-adjusted MRI-based predictors of multiple sclerosis disability
por: Kim, Yujin, et al.
Publicado: (2022)

Extensive Healthy Donor Age/Gender Adjustments and Propensity Score Matching Reveal Physiology of Multiple Sclerosis Through Immunophenotyping
por: Hannikainen, Paavali A., et al.
Publicado: (2020)

New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability
por: Weideman, Ann Marie, et al.
Publicado: (2017)

Enhancing the clinical value of serum neurofilament light chain measurement
por: Kosa, Peter, et al.
Publicado: (2022)

Smartphone-based symbol-digit modalities test reliably captures brain damage in multiple sclerosis
por: Pham, Linh, et al.
Publicado: (2021)

Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms
por: Kosa, Peter, et al.
Publicado: (2022)

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination
por: Lin, Yen Chih, et al.
Publicado: (2016)

Machine learning-optimized Combinatorial MRI scale (COMRISv2) correlates highly with cognitive and physical disability scales in Multiple Sclerosis patients
por: Kelly, Erin, et al.
Publicado: (2022)

No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)
por: Bonnan, Mickael, et al.
Publicado: (2021)

Assessment of Smartphone-Based Spiral Tracing in Multiple Sclerosis Reveals Intra-Individual Reproducibility as a Major Determinant of the Clinical Utility of the Digital Test
por: Messan, Komi S., et al.
Publicado: (2022)

A Complex Role of Herpes Viruses in the Disease Process of Multiple Sclerosis
por: Wuest, Simone C., et al.
Publicado: (2014)

Smartphone Level Test Measures Disability in Several Neurological Domains for Patients With Multiple Sclerosis
por: Boukhvalova, Alexandra K., et al.
Publicado: (2019)

Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: Quantification and correlation with clinical disability
por: Mina, Yair, et al.
Publicado: (2021)

Biomarkers in Multiple Sclerosis
por: Martin, Roland, et al.
Publicado: (2006)

1820. Efficacy of Pulse-Taper Corticosteroid Adjunctive Therapy for Refractory Non-HIV Cryptococcal Meningoencephalitis
por: Anjum, Seher, et al.
Publicado: (2019)

Current Status and Future Opportunities in Modeling Clinical Characteristics of Multiple Sclerosis
por: Liu, Joshua, et al.
Publicado: (2022)

Acute painful lumbosacral paresthesia after intrathecal rituximab
por: Bromberg, J. E. C., et al.
Publicado: (2011)

NeurEx: digitalized neurological examination offers a novel high‐resolution disability scale
por: Kosa, Peter, et al.
Publicado: (2018)

Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis
por: Panackal, Anil A., et al.
Publicado: (2015)

Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials
por: Zhang, Yinan, et al.
Publicado: (2020)

Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis
por: Burman, Joachim, et al.
Publicado: (2023)

Severe headache in primary Sjögren’s syndrome treated with intrathecal rituximab
por: Tjensvoll, Anne Bolette, et al.
Publicado: (2019)

Quantifications of CSF Apoptotic Bodies Do Not Provide Clinical Value in Multiple Sclerosis
por: Masvekar, Ruturaj, et al.
Publicado: (2019)

Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS)
por: Jia, Yan, et al.
Publicado: (2012)

Subacute neurological deficits and respiratory insufficiency due to intrathecal methotrexate
por: de Faber, Sjoerd I. P. J., et al.
Publicado: (2021)

Rituximab in patients with membranous nephropathy and kidney insufficiency
por: Guo, Yanhong, et al.
Publicado: (2022)

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
por: Weideman, Ann Marie, et al.
Publicado: (2017)

Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally
por: Svenningsson, Anders, et al.
Publicado: (2015)

Intrathecal Inflammation in Progressive Multiple Sclerosis
por: Monaco, Salvatore, et al.
Publicado: (2020)

Body Mass Index in Multiple Sclerosis modulates ceramide-induced DNA methylation and disease course
por: Castro, Kamilah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qr898mv5ae8f88cjv1tcu6vq4r